Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
March 21 2022 - 7:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced that President and Chief Executive
Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a
fireside chat at the Maxim Group 2022 Virtual Growth Conference on
Monday, March 28, 2022 at 12:30 p.m. ET. Dr. Ashburn will also
present a corporate overview, which will become available for
on-demand viewing on Monday, March 28, 2022 at 9:00 a.m. ET.
A live webcast of the fireside chat, as well as the on-demand
corporate presentation, will be available to conference attendees
from Monday, March 28 to Wednesday, March 30. Both presentations
can be accessed by visiting the Investors & Media section of
Oncorus’ website at https://investors.oncorus.com/.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
Herpes Simplex Virus (HSV) Platform and selectively self-amplifying
viral RNA (vRNA)/ lipid nanoparticle (LNP) Immunotherapy
Platform.
Designed to deliver next-generation viral immunotherapy impact,
our HSV Platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead HSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering selectively self-amplifying vRNA/LNP Immunotherapy
Platform involves a highly innovative, novel combination of RNA and
oncolytic virus-based modalities designed to realize the potential
of RNA medicines for cancer. Our lead IV-administered selectively
self-amplifying vRNA Immunotherapy clinical candidates, ONCR-021
and ONCR-788, are both currently in IND-enabling studies.
Please visit www.oncorus.com to learn more.
Investor
Contact:Stern Investor Relations Julie
SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Apr 2023 to Apr 2024